• Fapon Biotech has continuously developed and upgraded its raw materials solutions for Mpox antigen rapid tests.
• Leveraging its expertise, Fapon Biotech is committed to fighting this global public health issue and assisting its global partners in the development of Mpox diagnostic rapid tests.

Fapon Biotech is a global leader in the In-vitro Diagnostics (IVD) industry, with a steadfast commitment to advancing global health by providing innovative diagnostic solutions. As the World Health Organization (WHO) declared the Mpox (Monkeypox) outbreak a public health emergency of international concern (PHEIC) on August 14, Fapon Biotech reaffirmed its commitment by providing antigen diagnostic products to address this emerging threat.

Since the outbreak of Mpox in 2022, Fapon Biotech has been continuously developing and upgrading its raw materials solutions for Mpox antigen rapid tests. Fapon’s products for Mpox detection have high sensitivity and high specificity and demonstrate no cross-reactivity with non-OPXVs (Orthopoxvirus) such as the varicella-zoster virus. Fapon Biotech’s solutions are developed to offer more effective and accessible testing options, particularly for low—and middle-income countries and regions, thereby facilitating rapid diagnosis in such areas.

In 2023, the increased global circulation of the Mpox virus heightened the demand for diagnostics, altogether demonstrating a clear need for a simplified, automated, and accessible assay that is available outside laboratories. In response, to enhance access to quality-assured, accurate, and accessible Mpox diagnostics, WHO specified a target product profile designed for decentralized use, including in community settings. This measure has encouraged more IVD companies to develop POCT products that are more convenient and accessible for screening and diagnosis in rural environments and areas with limited healthcare resources.

In the ongoing battle against the spread of Mpox, Fapon Biotech stands committed to leveraging its expertise to fight this global public health issue and assist its global partners in the development of Mpox diagnostic rapid tests. To explore how Fapon Biotech can assist or collaborate, please use the green "Request Information" button below.

With over 20 years of experience, Fapon Biotech has played a pivotal role in developing IVD solutions to prevent the spread of infectious disease agents such as HIV, hepatitis C, syphilis, malaria, dengue, and respiratory diseases. Looking into the future, our extensive expertise in antibody design and cutting-edge technology, enables us to support the development of diagnostic tests that provide earlier detection and institution of treatment for the improvement of public health.